EGFR and non-small cell lung carcinoma: Gefitinib, a first-generation TKI, has shown improved survival outcomes, higher response rates, and significantly longer progression-free survival (PFS) relative to standard first-line chemotherapy in patients with advanced NSCLC harboring activating mutations of the EGFR gene and has been linked to enhanced tolerability and quality of life compared to chemotherapy [7–10].